{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:33:12Z","timestamp":1794313992236,"version":"4.9.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012997","name":"AASTMT","doi-asserted-by":"publisher","award":["2047"],"award-info":[{"award-number":["2047"]}],"id":[{"id":"10.13039\/100012997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.biopha.2025.118679","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T04:48:57Z","timestamp":1761281337000},"page":"118679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Design and synthesis of pyrazolopyrimidinone derivatives as dual VEGFR\/Aurora kinase inhibitors against hepatocellular and breast carcinomas"],"prefix":"10.1016","volume":"192","author":[{"given":"Kurls E.","family":"Anwer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Botros Y.","family":"Beshay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marium M.","family":"Shamaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6680-4448","authenticated-orcid":false,"given":"Nour E.A.","family":"Abd El-Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Senbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118679_bib1","unstructured":"World Health Organization. Health Topics: Cancer. \u3008https:\/\/www.who.int\/health-topics\/cancer\u3009 (accessed Feb 8, 2025)."},{"key":"10.1016\/j.biopha.2025.118679_bib2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3390\/cancers12020491","article-title":"Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma","volume":"12","author":"Dimri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2025.118679_bib3","first-page":"209","article-title":"CA cancer J. Clin","volume":"71","author":"Sung","year":"2021","journal-title":"CA a cancer journal clinicians"},{"key":"10.1016\/j.biopha.2025.118679_bib4","article-title":"GAS5 lncRNA: a biomarker and therapeutic target in breast cancer","volume":"260","author":"Thangavelu","year":"2024","journal-title":"Pathol. Res. Pr."},{"key":"10.1016\/j.biopha.2025.118679_bib5","unstructured":"World Health Organization. Breast cancer. \u3008https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast\u3009 (accessed Mar 13, 2025)."},{"key":"10.1016\/j.biopha.2025.118679_bib6","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2025.118679_bib7","author":"Kim","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2025.118679_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/14656566.2024.2340714","article-title":"Emerging therapies targeting growth factors in hepatocellular carcinoma","volume":"25","author":"Ruff","year":"2024","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.biopha.2025.118679_bib9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10238-024-01446-5","article-title":"Angiogenesis in breast cancer: insights and innovations","volume":"24","author":"Elayat","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.biopha.2025.118679_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","volume":"38","author":"Katoh","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.biopha.2025.118679_bib11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3181\/0901-MR-12","article-title":"The epidermal growth factor receptor: a link between inflammation and liver cancer","volume":"234","author":"Berasain","year":"2009","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"10.1016\/j.biopha.2025.118679_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/dna.2008.0823","article-title":"Epidermal growth factor genetic variation, breast cancer risk, and waiting time to onset of disease","volume":"28","author":"Ara\u00fajo","year":"2009","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.biopha.2025.118679_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-022-00110-2","article-title":"Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy","volume":"3","author":"Li","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.biopha.2025.118679_bib14","first-page":"5573","article-title":"BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K\/AKT\/mTOR pathway","volume":"11","author":"Li","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.biopha.2025.118679_bib15","first-page":"35505","article-title":"RSC adv","volume":"14","author":"Eissa","year":"2024"},{"key":"10.1016\/j.biopha.2025.118679_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.138641","article-title":"Integrated in silico and in vitro discovery of a new anticancer thiadiazole analog targeting VEGFR-2","volume":"1312","author":"Eissa","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.biopha.2025.118679_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2024.108221","article-title":"Anti-proliferative 2,3-dihydro-1,3,4-thiadiazoles targeting VEGFR-2: design, synthesis, in vitro, and in silico studies","volume":"113","author":"Elkady","year":"2024","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib18","doi-asserted-by":"crossref","first-page":"35505","DOI":"10.1039\/D4RA04158E","article-title":"Design, synthesis, and evaluation of novel thiadiazole derivatives as potent VEGFR-2 inhibitors: a comprehensive in vitro and in silico study","volume":"14","author":"Eissa","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.biopha.2025.118679_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107157","article-title":"Design, synthesis, and anticancer evaluation of N-sulfonylpiperidines as potential VEGFR-2 inhibitors, apoptotic inducers","volume":"145","author":"Elgammal","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib20","article-title":"arch. pharm. (Weinheim)","volume":"358","author":"Elkady","year":"2025","journal-title":"Arch. der Pharm."},{"key":"10.1016\/j.biopha.2025.118679_bib21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2025.118679_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2021.105926","volume":"163","author":"AboulMagd","year":"2021","journal-title":"Microchem. J."},{"key":"10.1016\/j.biopha.2025.118679_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4174\/astr.2017.93.5.252","article-title":"Prognostic factors after curative resection hepatocellular carcinoma and the surgeon's role","volume":"93","author":"You","year":"2017","journal-title":"Ann. Surg. Treat. Res."},{"key":"10.1016\/j.biopha.2025.118679_bib24","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2025.118679_bib25","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1634\/theoncologist.2010-0366","article-title":"Different annual recurrence pattern between lumpectomy and mastectomy: implication for breast cancer surveillance after breast-conserving surgery","volume":"16","author":"Yu","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2025.118679_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jamcollsurg.2006.10.004","article-title":"Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting milan criteria: rationale for partial hepatectomy as first strategy","volume":"204","author":"Tanaka","year":"2007","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.biopha.2025.118679_bib27","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/bjs.6011","article-title":"Aurora kinase b is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy","volume":"95","author":"Tanaka","year":"2008","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.biopha.2025.118679_bib28","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-1057-03","article-title":"Overexpression and amplification of Aurora-A in hepatocellular carcinoma","volume":"10","author":"Jeng","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118679_bib29","doi-asserted-by":"crossref","first-page":"12916","DOI":"10.18632\/oncotarget.2682","article-title":"Aurora-A promotes chemoresistance in hepatocelluar carcinoma by targeting NF-kappaB\/microRNA-21\/PTEN signaling pathway","volume":"5","author":"hang","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118679_bib30","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nrc1502","article-title":"Aurora-kinase inhibitors as anticancer agents","volume":"4","author":"Keen","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118679_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13641","article-title":"The role of aurora kinase a in hepatocellular carcinoma: unveiling the intriguing functions of a key but still underexplored factor in liver cancer","volume":"57","author":"Grisetti","year":"2024","journal-title":"Cell Prolif."},{"key":"10.1016\/j.biopha.2025.118679_bib32","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/onc.2016.292","article-title":"Aurora a kinase activates YAP signaling in triple-negative breast cancer","volume":"36","author":"Chang","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2025.118679_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118286","article-title":"Design, synthesis, and anticancer evaluation of new pyrazolo[3,4-d]pyrimidine-based derivatives: CDK2 inhibition, apoptosis-inducing activity, molecular modelling studies","volume":"128","author":"Hassan","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib34","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1039\/D0MD00227E","article-title":"Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold","volume":"11","author":"Baillache","year":"2020","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib35","article-title":"arch pharm (Weinheim)","volume":"353","author":"Kassab","year":"2020","journal-title":"Arch. der Pharm."},{"key":"10.1016\/j.biopha.2025.118679_bib36","article-title":"[G. M. - name unclear], H. M. aly, R. A. othman","volume":"7","author":"Saleh","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib37","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.bmcl.2012.01.019","article-title":"Synthesis, Sar and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidines as dual inhibitors of aurora kinases and CDK1","volume":"22","author":"Le Brazidec","year":"2012","journal-title":"Bioorg. Med Chem. Lett."},{"key":"10.1016\/j.biopha.2025.118679_bib38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.molliq.2017.12.156","volume":"252","author":"Sayed","year":"2018","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.biopha.2025.118679_bib39","doi-asserted-by":"crossref","first-page":"663","DOI":"10.21608\/ejchem.2016.1442","volume":"59","author":"Sayed","year":"2016","journal-title":"Egypt. J. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70139","article-title":"Comparative study of conventional, grinding, and Microwave-Assisted synthesis of aminopyrazolones and diaminopyrazoles: exploring the antitumor activity, dual CDK-2\/CA IX inhibition potential, and apoptosis induction","volume":"86","author":"Anwer","year":"2025","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.biopha.2025.118679_bib41","first-page":"1284","article-title":"New Pyrazole\/Pyrimidine-Based scaffolds as inhibitors of heat shock protein 90 endowed with apoptotic Anti-Breast cancer activity","volume":"17","author":"Al-Wahaibi","year":"2024","journal-title":"Pharm. (Basel)"},{"key":"10.1016\/j.biopha.2025.118679_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106397","article-title":"Exploring the cytotoxic effect and CDK-9 inhibition potential of novel sulfaguanidine-based azopyrazolidine-3,5-diones and 3,5-diaminoazopyrazoles","volume":"133","author":"Husseiny","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib43","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1007\/s00044-012-0343-0","article-title":"Synthesis of some new 3,5-diamino-4-(4\u2032-fluorophenylazo)-1-aryl\/heteroarylpyrazoles as antimicrobial agents","volume":"22","author":"Aggarwal","year":"2013","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.biopha.2025.118679_bib44","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.3390\/molecules26092708","volume":"26","author":"Arias-G\u00f3mez","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2025.118679_bib45","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1021\/je970167g","article-title":"Acidity constants of some hydroxy azo pyrazolopyrimidines in mixed Aqueous\u2212Organic solvents","volume":"43","author":"Rageh","year":"1998","journal-title":"J. Chem. Eng. Data."},{"key":"10.1016\/j.biopha.2025.118679_bib46","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s11164-015-2074-6","article-title":"Synthesis and anticancer activity of some new heterocyclic compounds based on 1-cyanoacetyl-3,5-dimethylpyrazole","volume":"42","author":"Metwally","year":"2016","journal-title":"Res. Chem. Intermed."},{"key":"10.1016\/j.biopha.2025.118679_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202402608","article-title":"Efficient synthesis and biological evaluation of some new Pyrazolo[1,5-a]pyrimidine derivatives as antimicrobial activity","volume":"9","author":"Abbas","year":"2024","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.biopha.2025.118679_bib48","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/jhet.3497","article-title":"Synthesis, characterization, and theoretical calculation of new azo dyes derived from [1,5-a]Pyrimidine-5-one having solvatochromic properties","volume":"56","author":"\u015eener","year":"2019","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib49","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1002\/jhet.2977","article-title":"Synthesis, characterization, solvatochromic properties, and Antimicrobial-radical scavenging activities of new diazo dyes derived from Pyrazolo[1,5-a]pyrimidine","volume":"54","author":"\u015eener","year":"2017","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib50","first-page":"203","article-title":"PMID","volume":"25","author":"Aggarwal","year":"2018","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1021\/jm00224a017","volume":"19","author":"Springer","year":"1976","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib52","article-title":"Pyrazolopyrimidine derivatives as kinase inhibitors","author":"Merck Sharp & Dohme","year":"2011","journal-title":"World Intellect. Prop. Organ."},{"key":"10.1016\/j.biopha.2025.118679_bib53","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/17568919.2025.2453409","article-title":"Dual VEGFR-2 and EGFR(T790M) inhibitors of phenyldiazenes: anticancer evaluations, ADMET, docking, design and synthesis","volume":"17","author":"Alsulaimany","year":"2025","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib54","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1080\/17568919.2024.2419363","article-title":"In vivo evaluation of novel synthetic pyrazolones as CDK9 inhibitors with enhanced pharmacokinetic properties","volume":"16","author":"Husseiny","year":"2024","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108746","article-title":"ADMET, docking, anticancer evaluations, design and synthesis of pyrazolo[1,5-a]pyrimidines substituted with furan and phenyldiazene as dual EGFRT790M and VEGFR-2 inhibitors","volume":"163","author":"Alsulaimany","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib56","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1134\/S107042802405018X","volume":"60","author":"Anwer","year":"2024","journal-title":"Russ. J. Org. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib57","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1134\/S1070428024020167","volume":"60","author":"Mehany","year":"2024","journal-title":"Russ. J. Org. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib58","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/jhet.3946","volume":"57","author":"Anwer","year":"2020","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105846","article-title":"Conventional and microwave-assisted synthesis, anticancer evaluation, (99m)Tc-coupling and In-vivo study of some novel pyrazolone derivatives","volume":"125","author":"Essa","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134798","article-title":"Novel annulated thiophene derivatives: synthesis, spectroscopic, X-ray, hirshfeld surface analysis, DFT, biological, cytotoxic and molecular docking studies","volume":"1276","author":"Anwer","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.biopha.2025.118679_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42714-w","article-title":"Synthesis, spectroscopic, DFT calculations, biological activity, Sar, and molecular docking studies of novel bioactive pyridine derivatives","volume":"13","author":"Anwer","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118679_bib62","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13065-023-01053-7","article-title":"Green synthesis of highly functionalized heterocyclic bearing pyrazole moiety for cancer-targeted chemo\/radioisotope therapy","volume":"17","author":"Anwer","year":"2023","journal-title":"BMC Chem."},{"issue":"1","key":"10.1016\/j.biopha.2025.118679_bib63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s40203-022-00125-1","article-title":"Optimizing the sunitinib for cardio-toxicity and thyro-toxicity by scaffold hopping approach","volume":"10","author":"Chaudhari","year":"2022","journal-title":"Silico Pharm."},{"key":"10.1016\/j.biopha.2025.118679_bib64","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1039\/D4MD00754A","article-title":"Probing structural requirements for thiazole-based mimetics of sunitinib as potent VEGFR-2 inhibitors","volume":"16","author":"Abd Elhameed","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304782","article-title":"Vorolanib, sunitinib, and axitinib: a comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects","volume":"19","author":"Bakri","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118679_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.201800520","article-title":"Synthesis, characterization and in\u2005vitro studies of a cathepsin B-Cleavable prodrug of the VEGFR inhibitor sunitinib","volume":"16","author":"Karnthaler-Benbakka","year":"2019","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.biopha.2025.118679_bib67","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-022-01310-7","article-title":"Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2025.118679_bib68","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3390\/molecules26061611","article-title":"7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-ones designed by a \"cut and glue\" strategy are dual aurora A\/VEGF-R kinase inhibitors","volume":"26","author":"Karatas","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2025.118679_bib69","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1158\/1535-7163.MCT-10-0574","article-title":"ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action","volume":"10","author":"Fletcher","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118679_bib70","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1016\/j.bmcl.2012.03.035","article-title":"Thienopyridine ureas as dual inhibitors of the VEGF and aurora kinase families","volume":"22","author":"Curtin","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2025.118679_bib71","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/cas.12701","article-title":"Novel aurora\/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma","volume":"106","author":"Nakao","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2025.118679_bib72","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13046-016-0464-2","article-title":"Antitumor activity of TY-011 against gastric cancer by inhibiting aurora A, aurora b and VEGFR2 kinases","volume":"35","author":"Liu","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118679_bib73","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13058-018-1014-y","article-title":"A phase II clinical trial of the aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer","volume":"20","author":"Diamond","year":"2018","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.biopha.2025.118679_bib74","doi-asserted-by":"crossref","first-page":"e1837","DOI":"10.1634\/theoncologist.2020-0093","volume":"25","author":"Abou-Alfa","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2025.118679_bib75","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1038\/s41598-019-43222-6","article-title":"A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)","volume":"9","author":"Veitch","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118679_bib76","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2210-10-14","article-title":"Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice","volume":"10","author":"Lim","year":"2010","journal-title":"BMC Pharm."},{"key":"10.1016\/j.biopha.2025.118679_bib77","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","article-title":"Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma","volume":"13","author":"Goodman","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118679_bib78","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cld.2016.08.009","article-title":"Drug hepatotoxicity: newer agents","volume":"21","author":"Bunchorntavakul","year":"2017","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.biopha.2025.118679_bib79","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000511249","article-title":"Sunitinib-Induced acute liver failure","volume":"15","author":"Aqsa","year":"2021","journal-title":"Case Rep. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.118679_bib80","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.1021\/jm300334d","article-title":"Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors","volume":"13","author":"Lawrence","year":"2012","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib81","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jmgm.2007.11.003","article-title":"Molecular docking\/dynamics studies of aurora a kinase inhibitors","volume":"26","author":"Talele","year":"2008","journal-title":"J. Mol. Graph. Model"},{"key":"10.1016\/j.biopha.2025.118679_bib82","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2025.118679_bib83","first-page":"330","article-title":"Design, Green synthesis and tailoring of vitamin e TPGS augmented niosomal Nano-Carrier of pyrazolopyrimidines as potential Anti-Liver and breast cancer agents with accentuated oral bioavailability","volume":"15","author":"Anwer","year":"2022","journal-title":"Pharm. (Basel)"},{"key":"10.1016\/j.biopha.2025.118679_bib84","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11030-018-9865-9","article-title":"Design, synthesis, cytotoxicity and molecular modeling studies of some novel fluorinated pyrazole-based heterocycles as anticancer and apoptosis-inducing agents","volume":"23","author":"Fayed","year":"2019","journal-title":"Mol. Divers"},{"key":"10.1016\/j.biopha.2025.118679_bib85","first-page":"77","article-title":"\"Isolation of B\u00f8yum AS. Isolation of mononuclear cells and granulocytes from human blood","volume":"97","author":"Boyum","year":"1968","journal-title":"J. Clin. Lab Invest"},{"key":"10.1016\/j.biopha.2025.118679_bib86","first-page":"179","volume":"79","author":"Morgan","year":"1998","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2025.118679_bib87","series-title":"The Protein Protocols Handbook","first-page":"17","author":"Kruger","year":"2009"},{"key":"10.1016\/j.biopha.2025.118679_bib88","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.biopha.2025.118679_bib89","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1007\/s13346-024-01530-z","article-title":"Preparation and characterization of sorafenib nano-emulsion: impact on pharmacokinetics and toxicity; an in vitro and in vivo study","volume":"14","author":"Zaafar","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.biopha.2025.118679_bib90","unstructured":"Dassault Syst\u00e8mes, BIOVIA Discovery Studio, Dassault Syst\u00e8mes, San Diego, 2024."},{"key":"10.1016\/j.biopha.2025.118679_bib91","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.biopha.2025.118679_bib92","unstructured":"L. Schr\u00f6dinger, W. DeLano, (2025). PyMOL. Retrieved from \u3008http:\/\/www.pymol.org\/\u3009."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500873X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500873X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:40:23Z","timestamp":1775781623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222500873X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":92,"alternative-id":["S075333222500873X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118679","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of pyrazolopyrimidinone derivatives as dual VEGFR\/Aurora kinase inhibitors against hepatocellular and breast carcinomas","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118679"}}